research Characteristics and predictive values of super-responders in alopecia areata under tofacitinib treatment: A single-center retrospective study
In this study, 37.5% of alopecia areata patients treated with tofacitinib were identified as super-responders, with significant predictors for this status being older age and no prior JAK inhibitor treatment, leading to faster and sustained hair regrowth.



